Megan Knight
Contatto Relazioni con gli Investitori presso LONGBOARD PHARMACEUTICALS, INC.
Profilo
Megan E.
Knight is currently the Vice President & Head-Investor Relations at Longboard Pharmaceuticals, Inc. Prior to her current position, she worked as the Director-Investor Relations at Arena Pharmaceuticals, Inc. from 2016 to 2020.
She also held the position of Head-Investor Relations & Corporate Communications at Senomyx, Inc. Ms. Knight completed her undergraduate degree at San Diego State University.
Posizioni attive di Megan Knight
| Società | Posizione | Inizio |
|---|---|---|
| LONGBOARD PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | 01/01/2021 |
Precedenti posizioni note di Megan Knight
| Società | Posizione | Fine |
|---|---|---|
| ARENA PHARMACEUTICALS | Contatto Relazioni con gli Investitori | 01/01/2020 |
| SENOMYX INC. | Contatto Relazioni con gli Investitori | - |
Formazione di Megan Knight
| San Diego State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LONGBOARD PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Senomyx, Inc.
 Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
- Borsa valori
- Insiders
- Megan Knight
